TapImmune broadens TPIV200 ’s Phase II trial for ovarian cancer
US-based immuno-oncology firm TapImmune has amended the Phase II clinical trial of its therapeutic peptide vaccine TPIV200 following discussions with the US Food and Drug Administration (FDA).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Food and Drug Administration (FDA) | Ovarian Cancer | Ovaries | Pharmaceuticals | Vaccines